the republic logo

Drugmaker Sanofi: Net profit rose 26 percent in 4th quarter on lower charge for drug Lemtrada


PARIS — Sanofi SA says its net profit soared 26.3 percent in the fourth quarter thanks to a lower charges against its Lemtrada multiple sclerosis treatment.

The world's third-largest drugmaker by sales reported net profit of 1.34 billion ($1.52 billion) in the period. Sanofi's year earlier earnings had been weighed down by a 919-million-euro charge mainly accounted for by a writedown on the value of Lemtrada.

The Paris-based company sacked CEO Christopher Viehbacher last October, citing a lack of communication with the board.

Interim boss Serge Weinberg told reporters on a conference call that the search for Viehbacher's replacement "is in the final stage" and that a new CEO would be named in the first quarter.

Think your friends should see this? Share it with them!

Story copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Feedback, Corrections and Other Requests: AP welcomes feedback and comments from readers. Send an email to and it will be forwarded to the appropriate editor or reporter.

We also have more stories about:
(click the phrases to see a list)


Follow The Republic:

All content copyright ©2015 The Republic, a division of Home News Enterprises unless otherwise noted.
All rights reserved. Privacy policy.